Back to search

Article

Niraparib-Related Pulmonary Embolism During Ovarian Cancer Therapy

2021-12-16

Abstract excerpt

Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib-related treatment adverse events, gastrointestinal disorders and haematological toxicities were most commonly...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3a2b8783-d56b-5d94-ac63-3348ab392887
DOI
10.21203/rs.3.rs-1128496/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Niraparib-Related Pulmonary Embolism During Ovarian Cancer TherapyDOI 10.21203/rs.3.rs-1128496/v1
Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity
Niraparib for the treatment of ovarian cancer.Semantic proximity
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World DataSemantic proximity
The role of niraparib for the treatment of ovarian cancer.Semantic proximity
Niraparib in ovarian cancer: results to date and clinical potentialSemantic proximity
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity
Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.Semantic proximity
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Semantic proximity
Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.Semantic proximity
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity
Select a neighboring publication to make it the new centre.